Chapter 4: Clinical Evaluation Data (临床评价资料)
NMPA Reference: Notice 2021-121, Attachment 5, Chapter 4
Document Code: NMPA-CH4
Responsible Party: Manufacturer (CRO supports clinical strategy and evaluation)
Requirements Checklist
4.1 Table of Contents
- [ ] All headings and sub-headings with page numbers
4.2 Clinical Evaluation Data Requirements (临床评价资料要求)
4.2.1 Product Description and R&D Background
- [ ] Basic device information
- [ ] Intended use
- [ ] Existing diagnostic or treatment methods and related medical device clinical applications
- [ ] Relationship between the device and existing methods
- [ ] Expected clinical outcomes
4.2.2 Scope of Clinical Evaluation
- [ ] Define which aspects of the device are covered by clinical evaluation
- [ ] For parts exempt from clinical evaluation: describe structure/composition and justify exemption
4.2.3 Clinical Evaluation Pathway Selection
Select the appropriate pathway based on intended use, technical characteristics, and existing clinical data:
Pathway 1: Equivalent Device (同品种临床评价路径)
- [ ] Comparison of intended use between subject and equivalent device
- [ ] Comparison of technical characteristics
- [ ] Comparison of biological characteristics
- [ ] Collection, evaluation, and analysis of clinical data from equivalent device(s) to form clinical evidence
- [ ] For identified differences: scientific evidence demonstrating equivalent safety and efficacy
Pathway 2: Clinical Trial (临床试验路径)
- [ ] Clinical trial protocol (方案)
- [ ] Ethics committee approval from each trial institution
- [ ] Clinical trial report (报告)
- [ ] Informed consent form template
- [ ] Clinical trial database (raw database, analysis database, documentation, program code)
- File formats: PDF, Word (editable), Excel, XPT, TXT as appropriate
Pathway 3: Exemption from Clinical Evaluation (免于临床评价)
- [ ] Product is listed in the "Medical Device Catalogue Exempt from Clinical Evaluation"
- [ ] Comparison with exempt catalogue product per NMPA Guidance Principles
- [ ] Demonstrate equivalence in: basic principle, structure, performance, safety, intended use
4.3 Other Data
- [ ] Summary, report, and data for applicable evaluation items (if applicable)
Clinical Evaluation Pathways -- Decision Flowchart
Is the device on the Clinical Evaluation Exemption List?
|
YES --> Pathway 3: Prepare comparison documentation per guidance
|
NO --> Is a suitable equivalent (同品种) device available?
|
YES --> Can differences be scientifically justified?
| |
| YES --> Pathway 1: Equivalent device evaluation
| |
| NO --> Pathway 2: Clinical trial required
|
NO --> Pathway 2: Clinical trial requiredComparison with EU MDR
| Aspect | NMPA Ch.4 | EU MDR (Article 61, Annex XIV) |
|---|---|---|
| Pathways | 3: Equivalent / Clinical Trial / Exemption | CEP+CER+PMCF (all classes; equivalence per Annex XIV) |
| Equivalence | 同品种 comparison (technical, intended use, biological) | Technical, biological, clinical equivalence (Annex XIV, Part A) |
| Exemption | Published exemption list for Class II/III | No exemption mechanism (all devices require CE) |
| Trial requirements | Protocol + Ethics + Report + Informed Consent + Database | Similar + CIP per Annex XV |
| Post-market clinical | Not part of registration dossier (separate PMS system) | PMCF mandatory, integrated into CER updates |
| Class I | Registration only, no clinical evaluation | Still requires clinical evaluation (proportionate) |
| Literature review | Part of equivalent device pathway, no standalone literature pathway | Standalone literature review pathway available |
Key Standards & References
- Notice 2021-121, Attachment 5, Chapter 4
- Administrative Measures for Medical Device Clinical Trial (Order No. 4, 2023 Revision)
- Guidance Principles for Clinical Evaluation of Medical Devices (通用指导原则)
- List of Medical Devices Exempt from Clinical Evaluation (updated periodically)
- Guidance Principles for Clinical Evaluation via Equivalent Device (同品种临床评价指导原则)
- GB/T 42062-2022: Risk management (for clinical risk context)

